"Our tasks are now to deliver substantial growth with more customers signing up, increasingly by word of mouth, and to deliver more services to those customers to ensure they are increasingly successful and that we return increased fees per customer."
Volpara's technology focuses on early detection of breast cancer and it went public last year, choosing the ASX over a domestic listing.
The shares were sold at 50 Australian cents apiece, raising A$10 million in an initial public offering in 2016, and it went back to investors seeking another A$10 million at 60 Australian cents apiece later that year.
The shares closed at 64 Australian cents yesterday, and have edged up 0.8 per cent this year.
The company increased its spending on R&D to $1.5 million in the six-month period from $1.2 million a year earlier, while sales and marketing expenses shrank to $2.6 million from $2.7 million.
Operating cash burn slowed to $3.4 million from $3.8 million and the company had cash and equivalents of $1.3 million as at September 30, plus a further $8 million in term deposits.